RNASE1 and triple-A syndrome: In conclusion, while circulating exDNA showed AAA biomarker potential, targeting exRNA by systemic RNase A treatment effectively mitigated aneurysm progression in established disease through pleiotropic modulation of inflammation and tissue remodeling, presenting a novel and promising therapeutic strategy.